Bicara Therapeutics Inc. Announces Board Changes; Two Directors Appointed

What Happened
Bicara Therapeutics filed an 8-K on July 28, 2026 reporting that longtime director Kiran Mazumdar-Shaw resigned from the board and the Nominating & Corporate Governance Committee (resignation submitted July 23, effective July 28, 2026). The board appointed Jeremy Bender, Ph.D. (Class I, term to 2028) and Christy Oliger (Class II, term to 2029) effective July 28, 2026, and increased the board size from nine to ten. Both appointees were determined to be independent under Nasdaq rules.

Key Details

• Resignation: Kiran Mazumdar-Shaw resigned effective July 28, 2026; company states resignation was not due to any disagreement with the company.
• Appointments: Jeremy Bender, Ph.D. (appointed July 26, effective July 28) — Class I director through 2028; Christy Oliger — Class II director through 2029.
• Board size and independence: Board increased from nine to ten directors; both new directors are independent and Dr. Bender meets Nasdaq/Exchange Act audit committee independence requirements.
• Compensation and agreements: Each non-employee director will receive an initial non‑qualified stock option award of 38,950 shares plus cash board/committee pay under the company’s director compensation policy (policy to be filed in the 10-Q for quarter ending Sept 30, 2026). Both new directors signed the company’s standard indemnification agreement.
• Committee changes: Dr. Bender joined the Audit Committee (replacing Carolyn Ng); Ms. Oliger and Dr. Ng joined the Nominating & Corporate Governance Committee (replacing Ms. Mazumdar‑Shaw and Jake Simson). A new Launch Readiness Committee was formed (Kate Haviland, chair; members Kate Haviland, Jeremy Bender, Christy Oliger). Michael Powell remains Board Chair.

Why It Matters
Board composition and committee memberships affect corporate governance and oversight. The creation of a Launch Readiness Committee signals the board is focusing on commercialization and launch planning—important for investors tracking Bicara’s path to market. Stock option awards to new independent directors (38,950 shares each) are a routine part of director compensation but represent potential dilution. The filing also confirms there were no disclosed disagreements tied to the resignation and no related‑party transactions involving the new directors.